Working with Us

2023 PD Therapeutics Conference

Join the Waitlist

About the Conference

*At this time, there are no current CDC guideline or local rules and regulations in place for COVID-19. As such, this meeting will not require proof of vaccination or testing, and while masking is encouraged, it will be optional. As the course of the pandemic shifts or local, state or federal regulations change, we will follow science and update all attendees. For international attendees, please make sure to check the rules on arrival and departure with your country and the United States. The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 15th Annual PD Therapeutics Conference is scheduled to be held on October 19, 2023, in New York.

Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.

Registration is at capacity. Please click on the link below to join the waitlist. Thank you.

JOIN THE WAITLIST HERE >

For Questions or Updates,

Please contact researchmeetings@michaeljfox.org.

Conference Schedule (subject to change)

7:45

ARRIVALS & BREAKFAST

8:30-8:45

WELCOME REMARKS

Sohini Chowdhury | The Michael J. Fox Foundation

8:45-11:10

Session 1: Advances in Emerging Targets and Therapeutic Development

SESSION INTRODUCTION by Session Chair

Session Chair: Karoly Nikolich, PhD | Alkahest Inc.

GP2- Globalizing Parkinson’s Disease Genetics

Speaker: Andrew Singleton, PhD | National Institutes of Health

Transcriptomic analysis in PPMI/AMP-PD

Speaker: Kendall Van Keuren-Jensen, PhD | Translational Genomics Research Institute

Identification of TMEM175 Activators as Candidate Disease-Modification Therapeutics for Parkinson Disease

Speaker: David Stone, PhD | Cerevel Therapeutics

Development of USP30 Inhibitors for Parkinson’s Disease

Speaker: Paul Thompson, PhD | Mission Therapeutics

Kv1.3 Blockade to Resolve Neuroinflammation in Parkinson's Disease

Speaker: Niels Plath, PhD | Muna Therapeutics

CLOSING REMARKS from Session Chair

Karoly Nikolich, PhD | Alkahest Inc.

10:40 - 11:10

Networking Break / Poster Viewing

11:10 - 12:20

Session 2: Advances in the Classification and Measurement of Parkinson's

SESSION INTRODUCTION by Session Chair

Kathleen Poston, MD, MS | Stanford University

Neuropathology of Lewy Body Diseases

Speaker: Tom Montine, MD, PhD | Stanford University

The PD Integrated Staging System

Speaker: Ken Marek, MD | Institute of Neurodegenerative Disorders

a-synuclein SAA: Today and Future Prospects

Speaker: Kalpana Merchant, PhD | TransThera Consulting

12:20 - 1:25

Networking Break / Poster Viewing / Lunch

Overview of MJFF Molecular Imaging Consortium

Speaker: Jamie Eberling, PhD | The Michael J. Fox Foundation

Digital Measures in Parkinson’s Disease: WATCH-PD Study

Speaker: Jamie Adams, MD | University of Rochester

De-risking Therapeutic Development: The Power of Mitophagy Biomarkers in PD

Speaker: Bill Shrader, PhD | AcureX

CLOSING REMARKS from Session Chair

Kathleen Poston, MD, MS | Stanford University

2:40 - 3:10

Networking Break / Poster Viewing

3:10 - 4:40

Session 3: Panel Discussions

Applying the PD-Integrated Staging System to Clinical Trials

Moderator: Karl Kieburtz, MD, MPH | University of Rochester; Panelists: Gennaro Pagano, MD, PhD | Roche; Tien Dam, MD | Biogen; Tanya Fischer, MD, PhD | Biohaven

Advancing the use of Patient Voice to Drive Successful R&D

CLOSING REMARKS

Speaker: Sohini Chowdhury | The Michael J. Fox Foundation

4:40 - 6:00

Cocktail Reception / Poster Viewing

Speakers

Jamie Adams, MD | University of Rochester

Tien Dam, MD | Biogen

Vicky DiBiaso, PhD | Sanofi

Jamie Eberling, PhD | The Michael J. Fox Foundation

Tanya Fischer, MD, PhD | Biohaven

Alison Handler, PharmD, RPh | Novartis

Karl Kieburtz, MD, MPH | University of Rochester

Catherine Kopil, PhD | The Michael J. Fox Foundation

Ken Marek, MD | Institute for Neurodegenerative Disorders

Soania Mathur, MD | MJFF Patient Council Member

Kalpana Merchant, PhD | TransThera Consulting

Tom Montine, MD, PhD | Stanford University

Karoly Nikolich, PhD | Alkahest Inc.

Gennaro Pagano, MD, PhD | Roche

Niels Plath, PhD | Muna Therapeutics

Kathleen Poston, MD, MS | Stanford University

Gary Rafaloff | MJFF Patient Council Member

Andrew Singleton, PhD | National Institutes of Health

David Stone, PhD | Cerevel Therapeutics

Bill Shrader, PhD | AcureX

Paul Thompson, PhD | Mission Therapeutics

Kendall Van Keuren-Jensen, PhD | Translational Genomics Research Institute

Posters

Poster Presentations

Path to Prevention (P2P) Trial: Study Design and Status Update

Tanya Simuni, MD | Northwestern University

A Machine Learning Contest to Automatically Detect Freezing of Gait: Results and Insights

Jeff Hausdorff, PhD | Tel Aviv Medical Center

Aligning with Regulators to Advance Patient-Reported Outcome Assessments that are Fit-for-Purpose in Early-Stage Parkinson’s Disease Clinical Trials

Diane Stephenson, PhD | Critical Path Institute

The London-Dhaka Project – the Prevalence and Assessment of Cognitive Impairment in Parkinson’s Disease

Alastair Noyce, MSc, MRCP, PhD, FHEA | Queen Mary University of London

Hit-to-Lead STING Inhibitor Small Molecule Development for Parkinson’s Disease

,John Streiff, PhD | AeroNeph Therapeutics

The Lysosomal Polyamine Transporter ATP13A2, an Emerging Drug Target for Parkinson’s Disease

Peter Vangheluwe, PhD | KU Leuven

MJFF Tools Overview

Nicole Polinski, PhD | MJFF

The National Plan to End Parkinson’s Act

Dustin Watson | MJFF